Morgan Stanley’s Impact BioMedical IBO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.13K Buy
738
+2
+0.3% +$12 ﹤0.01% 7304
2026
Q2
$4.27K Buy
736
+1
+0.1% +$7 ﹤0.01% 7247
2026
Q1
$5.56K Buy
735
+1
+0.1% +$6 ﹤0.01% 7111
2025
Q4
$4.68K Hold
734
– – ﹤0.01% 7080
2025
Q3
$6.16K Buy
+734
New +$5.84K ﹤0.01% 7038
2025
Q2
– Sell
-618
Closed -$6.79K – 8311
2025
Q1
$6.79K Buy
+618
New +$13.5K ﹤0.01% 6913
2024
Q4
– Sell
-5
Closed -$116 – 8133
2024
Q3
$116 Buy
+5
New +$149 ﹤0.01% 7423

Other funds holding IBO

Morgan Stanley's IBO Position: Q3 2026 in Review

Morgan Stanley increased its Impact BioMedical (IBO) stake by 0.27% in Q3 2026, buying an estimated $12 and bringing the position to 738 shares worth $4.13K. The position accounts for ﹤0.01% of the portfolio, ranked #7304.

Morgan Stanley first reported a position in IBO in Q3 2024 and has held it in 7 quarters since. The position peaked at $6.79K in Q1 2025. 19 funds tracked by Wall St. Rank hold IBO as of Q3 2026.

  • Morgan Stanley held 738 shares of Impact BioMedical worth $4.13K as of Q3 2026.
  • Morgan Stanley bought 2 Impact BioMedical shares in Q3 2026, an estimated $12.
  • Impact BioMedical made up ﹤0.01% of Morgan Stanley's portfolio in Q3 2026, its #7304 holding.
  • Morgan Stanley first reported a position in Impact BioMedical in Q3 2024 and has held it in 7 quarters since.
  • Morgan Stanley's Impact BioMedical position peaked at $6.79K in Q1 2025.
  • 19 funds tracked by Wall St. Rank held Impact BioMedical as of Q3 2026.

Based on Morgan Stanley's 13F filing for Q3 2026, filed 13 Nov 2026.